dr. reddys posts
FeedPosted Jun 21st 2010 11:10AM by Steven Halpern (RSS feed)
Filed under: International Markets, India, Newsletters, Stocks to Buy
"Modern drugs are expensive to develop; but after just 20 years, a drug can be duplicated by generic drug manufacturers and sold to those who need it for far less money," says Paul Goodwin.
The editor of Cabot China & Emerging Markets Report explains, "That's where Dr. Reddy's Laboratories (RDY) comes in. Founded in 1984 by Dr. Anji Reddy, Dr. Reddy's Labs is the main reason India has gone from a net drug importer to a net drug exporter.
"Dr. Reddy's is a growing global power in the pharmaceutical business, with a lineup of more than 50 products offered in the U.S., more than 160 products marketed in Europe, and more than 200 branded formulations available in India, Russia and other emerging markets.
Continue reading Dr. Reddy's (RDY): A 'Generic Revolution'
Posted Jul 16th 2009 1:00PM by Steven Halpern (RSS feed)
Filed under: International Markets, India, China, Newsletters, Stocks to Buy, China Mobile Limited (CHL)
"Inflationary fears and the desire to generate higher returns in non-dollar assets should boost BRIC stocks (Brazil, Russia, India and China)," says Chuck Carlson in his The DRIP Investor.
"Despite the run-up this year, BRIC stock markets are still reasonably valued. Russia, India, and Brazil all trade at price/earnings ratios similar to the U.S.
"And while China's stock market does trade at a premium to the U.S., China's economic growth will swamp that of the U.S. this year and for the foreseeable future.
Continue reading 'Compelling case' for China and India
Posted Jun 11th 2009 1:30PM by Steven Halpern (RSS feed)
Filed under: India, Newsletters, Stocks to Buy
"India-based Dr. Reddy's Laboratories (NYSE: RDY), a generic-drugs play with solid market positions in India, Russia, the US and Germany," says Asian stock expert Yiannis Mostrous.
In his specialty newsletter, The Silk Road Investor, he explains why he has chosen the firm as his latest "Stock of the month".
"Seventy percent of the firm's growth comes from generic drugs, and the trend there has been favorable. New products, market share gains and a revamp of the supply chain in India should contribute to profitability. The company is also building a proprietary pipeline to supplement it core business.
Continue reading Dr. Reddy's (RDY): Get ready for generic gains
Posted Oct 3rd 2008 9:30AM by Steven Halpern (RSS feed)
Filed under: Microsoft (MSFT), Apple Inc (AAPL), Time Warner (TWX), India, China, Brazil, Newsletters, Mutual Funds, Comcast Cl'A' (CMCSA), Merck and Co (MRK), Canada, , Barclays plc ADS (BCS), EOG Resources (EOG), Presidential Elections, Commodities, Oil, Agriculture, Stocks to Buy, Technology, General Dynamics Corp (GD), Israel, Green Stocks, Northrop Grumman (NOC)